Morning. Welcome to the 2026 Annual Meeting of Stockholders of Lifecore Biomedical, Inc. I am Paul Josephs, Lifecore's President and Chief Executive Officer, and I will be acting as Chairperson for this meeting. On behalf of the entire Board, officers, and employees, I would like to thank you for attending this meeting. Natalie Hairston of American Election Services LLC has been appointed as the Inspector of Elections. Natalie has taken and subscribed to the customary oath of the office to execute her duties with strict impartiality. We will file this oath with the records of the meeting. I have been advised by our Inspector of Elections that a quorum is present. This meeting is now officially called to order. The polls are open for voting, and all our stockholders entitled to vote have the ability to do so online. If you encounter any technical difficulties accessing or participating in the e-meeting, please refer to the support link on the Annual Meeting webpage to reach the support team. Upon joining the meeting electronically, you will see an agenda for the meeting on your screen. At the bottom of the screen is a list of the rules of conduct for the meeting. In order to conduct an orderly meeting, we ask that all participants abide by these rules. We appreciate your cooperation in this matter. Also attending online today are Tom Salus, our Chief Legal and Administration Officer and Corporate Secretary, who will act as the Secretary of the Meeting and will record the minutes of the meeting. I would also like to introduce John Celi of KPMG LLP, the company's independent registered public accounting firm, who is in attendance virtually and available to respond to appropriate questions as needed. Please note that this meeting is being recorded. However, no one attending via the webcast is permitted to use any recording device. We will now conduct the formal business of this Annual Meeting as set forth in the notice of meeting and proxy statement, which was mailed beginning on April 24th, 2026 to stockholders as of the record date of April 6th, 2026. The four proposals to be voted on at this meeting are listed in the proxy statement. Any stockholders who have joined the meeting via live audio webcast and who have not already submitted a proxy and wish to vote their shares or wish to change their vote may do so by clicking on the Vote Here button on their screen during the meeting until the polls are closed. As a reminder, holders of common stock are entitled to vote one vote for each share of common stock outstanding as of the record date. Each holder of Series A preferred stock is entitled to the whole number of votes equal to the number of shares of common stock into which such holder's shares of Series A preferred stock would be convertible on the record date. As further described in the proxy statement, except as otherwise stated, holders of Series A preferred stock are entitled to vote with the holders of the shares of common stock on all matters submitted to a vote of holders of shares of common stock. Voting together with the holders of shares of common stock as one class on an as-converted basis, subject to certain conversion limits. After we review the proposals, we will answer any questions relating to the proposals before closing the polls and announcing preliminary voting results. We will not accept proxies, revocations, or changes after the closing of the polls. Questions may be submitted electronically through the Ask a Question field on the web portal. Out of consideration for others, we kindly request that each stockholder limit themselves to one question and that all questions be related to the proposals. Tom Salus, our Chief Legal and Administration Officer and Corporate Secretary, will now review the proposals. Thank you, Paul. The first proposal to be considered is the election of directors. nine directors are to be elected, two solely by the holders of the company's Series A Preferred Stock and seven by the holders of both the company's common stock and Series A Preferred Stock, voting together as if they were a single class. Each director, if elected, will serve until the next Annual Meeting of stockholders and their successors are elected and qualified or until his or her death, resignation, or removal. The directors are to be elected by a majority of votes cast by stockholders entitled to vote with respect to such director. The nominated candidates for director are Katrina Houde, Humberto C. Antunes, Paul H. Johnson, Paul Josephs, Matthew E. Korenberg, Nelson Obus, Joshua E. Schechter, Jason Aryeh as a Series A Preferred Director, and Christopher S. Kiper as a Series A Preferred Director. The Board unanimously recommends that you vote for the election of each of the nine named director nominees. The second proposal to be considered is the ratification of the appointment of KPMG LLP as the company's independent registered public accounting firm for the fiscal year ending December 31st, 2026. This proposal must be approved by an affirmative vote of the holders of shares representing a majority of the voting power cast with respect to this proposal. The Board unanimously recommends that you vote for this proposal. The third proposal to be considered is a non-binding advisory vote on the executive compensation of the company's named executive officers as described in the proxy statement. This advisory proposal will be approved if an affirmative vote of the holders of shares representing a majority of the voting power is cast with respect to this proposal. The Board unanimously recommends that you vote for this proposal. The fourth proposal to be considered is the approval of the Lifecore Biomedical, Inc. 2026 Stock Incentive Plan. This proposal must be approved by an affirmative vote of the holders of shares representing a majority of the voting power cast with respect to this proposal. The Board unanimously recommends that you vote for this proposal. If you have questions relating to the proposals, we will consider them now. There are no questions relating to the proposals. Since the commencement of the meeting at 10:30 A.M. Central Time, the polls have been open for stockholders to vote. Stockholders who have voted by proxy need not vote again, and the vote indicated on your proxy will be counted unless you wish to change your vote. If you have not already voted or you wish to change your vote, you may do so now by clicking on the voting button on the web portal and following the instructions there. We will now pause for a brief time to allow for voting. If you intend to cast or change your vote, please do so now as the polls will close momentarily. Thank you, everyone. I will now declare the polls closed. I've been advised that the Inspector of Elections has completed the preliminary vote count. The Inspector of Elections has informed me that based on the preliminary voting results, there are sufficient votes, one, in favor of the named nominees for director to elect all the nominees. Two, in favor of ratifying the selection of KPMG LLP as the company's independent registered public accounting firm for fiscal year ended December 31st, 2026. Three, in favor of the compensation of the named executive officers set forth in the proxy statement. Four, in favor of approving the Lifecore Biomedical, Inc. 2026 Stock Incentive Plan. Accordingly, I hereby declare that subject to the finalization of the final report on the results of this meeting, each of the proposals presented to the stockholders has been approved. The Inspector of Elections will prepare a final report certifying the election results that will be included as part of the record of this meeting. The final voting results will be included in the company's current report on Form 8-K to be filed with the Securities and Exchange Commission within four business days following this meeting. We have no other business to conduct at this meeting. The meeting is now adjourned. On behalf of Paul Josephs and the entire Lifecore Board of Directors, I would like to thank you all for attending this year's Annual Meeting of the Stockholders. We hope you share our excitement about Lifecore and look forward to speaking to you again next year.